Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.

Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH, Im SA, Sarosiek T, Chatterjee S, Wojtukiewicz MZ, Shparyk Y, Moiseyenko V, Bello M 3rd, Semiglazov V, Lee Y, Lim J.

Eur J Cancer. 2018 Apr;93:19-27. doi: 10.1016/j.ejca.2018.01.072. Epub 2018 Feb 12.

2.

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH, Vinnyk Y, Im SA, Sarosiek T, Chatterjee S, Wojtukiewicz MZ, Moiseyenko V, Shparyk Y, Bello M 3rd, Semiglazov V, Song S, Lim J.

J Clin Oncol. 2018 Apr 1;36(10):968-974. doi: 10.1200/JCO.2017.74.0126. Epub 2018 Jan 26.

PMID:
29373094
3.

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.

Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I.

JAMA Oncol. 2018 Mar 1;4(3):302-308. doi: 10.1001/jamaoncol.2017.4612.

PMID:
29327055
4.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Jan 1;29(1):281-282. doi: 10.1093/annonc/mdx543. No abstract available.

PMID:
29045519
5.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308.

PMID:
28838210
6.

[Hyperthermic intraperitoneal chemotherapy combined with cytoreductive procedure in patients with peritoneal pseudomyxoma].

Gafton GI, Senchik KY, Kireeva GS, Petrov VG, Semiglazov VV, Guseynov KD, Bespalov VG, Belyaeva OA, Belyaev AM.

Khirurgiia (Mosk). 2016;(5):26-30. doi: 10.17116/hirurgia2016526-30. Russian.

PMID:
27271716
7.

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P.

Lancet Oncol. 2016 Jun;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7. Epub 2016 May 11.

PMID:
27179402
8.

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

Mackey JR, Pieńkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press MF, Sauter G, Lindsay M, Houé V, Buyse M, Drevot P, Hitier S, Bensfia S, Eiermann W; Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 investigators.

Ann Oncol. 2016 Jun;27(6):1041-7. doi: 10.1093/annonc/mdw098. Epub 2016 Mar 2.

PMID:
26940688
9.

Regeneration and Cicatrization.

Pechersky AV, Pechersky VI, Shpilenya ES, Gaziev AH, Semiglazov VF.

J Stem Cells. 2016;11(2):89-97. Review.

PMID:
28296867
10.

Immune System and Regeneration.

Pechersky AV, Pechersky VI, Aseev MV, Droblenkov AV, Semiglazov VF.

J Stem Cells. 2016;11(2):69-87. Review.

PMID:
28296866
11.

[Use of SPECT-CT for visualization of sentinel lymph nodes in breast cancer patients].

Krzhivitsky PI, Kanaev SV, Novikov SN, Chernaya AV, Krivorotko PV, Semiglazov VF, Semenov II, Ponomareva OI, Iliin ND, Zhukova LA.

Vopr Onkol. 2015;61(4):624-8. Russian.

PMID:
26571834
12.

[Lateral metastasis in rectal cancer].

Zakharenko AA, Semiglazov VV, Kanaev SV, Beliaev MA, Morozov AN, Statsenko AA.

Vestn Khir Im I I Grek. 2015;174(3):103-7. Review. Russian. No abstract available.

PMID:
26390601
13.

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV, Tseng LM, Liu MC, Lluch A, Galeota E, Magazzù D, de la Haba-Rodríguez J, Oh DY, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L.

Ann Oncol. 2015 Dec;26(12):2429-36. doi: 10.1093/annonc/mdv395. Epub 2015 Sep 19.

PMID:
26387142
14.

[AUTOLOGOUS TRANSPLANTATION OF ADIPOSE TISSUE IN RECONSTRUCTIVE AND PLASTIC SURGERY. NEW POSSIBILITIES OF "OLD" MATERIAL].

Ivanov VG, Fedosov SI, Ermilova EV, Volokh MA, Zhiltsova EK, Ivanova OA, Semiglazov VF.

Vopr Onkol. 2015;61(3):460-6. Russian.

PMID:
26242162
15.

[PHOTODYNAMIC THERAPY FOR INTRADERMAL METASTASES OF BREAST CANCER USING THE MATRIX LIGHT-EMITTING DIODES APPARATUS LATUS].

Gelfond ML, Ivanov VG, Semiglazov VF, Vorotnikov VV, Belousova TA, Zhiltsova EK, Ivanova OA, Ermilova EV, Fedosov SI.

Vopr Onkol. 2015;61(3):430-4. Russian.

PMID:
26242157
16.

[METHODOLOGIC PROBLEMS OF SENTINEL LYMPH NODE BIOPSY IN PATIENTS WITH BREAST CANCER].

Krivorotko PV, Kanaev SV, Semiglazov VF, Novikov SN, Krzhivitsky PI, Semenov II, Turkevich EA, Busko EA, Donskikh RV, Bryantseva ZhV, Piskunov EA, Trufanova ES, Chernaya AV.

Vopr Onkol. 2015;61(3):418-23. Russian.

PMID:
26242155
17.

[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].

Semiglazov VF, Semiglazov VV, Petrenko OL, Komyakhov AV, Dashyan GA, Paltuev RM, Semiglazova TY, Manikhas AG, Bozhok AA, Lalak IA.

Vopr Onkol. 2015;61(3):381-6. Russian.

PMID:
26242149
18.

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.

Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, Stiegler G, Singh P, Schwebig A, Kramer S, Harbeck N.

Ann Oncol. 2015 Sep;26(9):1948-53. doi: 10.1093/annonc/mdv281. Epub 2015 Jun 28.

19.

[The role of scintimammography with 99mTs-technetril to predict the pathologic status of regional lymph nodes in patients with locally advanced breast cancer after neoadjuvant chemotherapy].

Bryantseva ZhV, Kanaev SV, Semiglazov VF, Novikov SN, Krivorotko PV, Klimenko VV, Trufanova ES, Kotova ZS, Chernaya AV, Turkevich EA, Semiglazova TY.

Vopr Onkol. 2015;61(2):185-8. Russian.

PMID:
26087595
20.

[The role of breast cancer stem cells in metastasis].

Dashyan GA, Semiglazov VF, Donskikh RV, Semiglazova TY, Vorotnikov VV, Apollonova VS.

Vopr Onkol. 2015;61(2):169-73. Review. Russian.

PMID:
26087592
21.

[Neoadjuvant systemic therapy for breast cancer].

Semiglazov VF.

Vopr Onkol. 2015;61(2):162-8. Review. Russian.

PMID:
26087591
22.

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, Hatzis C, Hudis CA, Pedrazzoli P, Sapino A, Semiglazov V, Von Minckwitz G, Simoncini EL, Jacobs MA, Barry P, Kühn T, Darby S, Hermelink K, Symmans F, Gennari A, Schiavon G, Dogliotti L, Berruti A, Bottini A.

J Natl Cancer Inst Monogr. 2015 May;2015(51):90-6. doi: 10.1093/jncimonographs/lgv023.

23.

RECIST for Response (Clinical and Imaging) in Neoadjuvant Clinical Trials in Operable Breast Cancer.

Semiglazov V.

J Natl Cancer Inst Monogr. 2015 May;2015(51):21-3. doi: 10.1093/jncimonographs/lgv021.

PMID:
26063880
24.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group.

N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.

25.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V.

J Clin Oncol. 2015 May 10;33(14):1564-73. doi: 10.1200/JCO.2014.57.1794. Epub 2015 Jan 20.

PMID:
25605838
26.

[Microviscosity of erythrocyte membranes in breast cancer patients: connection with the receptor phenotype of the tumor].

Tsyrlina EV, Kriukova OG, Poroshina TE, Tyrkevich EA, Barash NIu, Mullakhmetova ZI, Semiglazov VF, Bershteĭn LM.

Vopr Onkol. 2014;60(4):504-9. Russian.

PMID:
25552073
27.

Regeneration and Carcinogenesis.

Pechersky AV, Pechersky VI, Smolyaninov AB, Velyaninov VN, Adylov SF, Shmelev AY, Pecherskaya OV, Semiglazov VF.

J Stem Cells. 2015;10(4):255-70.

PMID:
27228582
28.

Comparison of two treatment strategies for irradiation of regional lymph nodes in patients with breast cancer: Lymph flow guided portals versus standard radiation fields.

Novikov SN, Kanaev SV, Semiglazov VF, Jukova LA, Krzhivitckiy PI.

Rep Pract Oncol Radiother. 2014 Jul 19;20(1):27-31. doi: 10.1016/j.rpor.2014.06.001. eCollection 2015 Jan.

29.

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.

Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, Hillenbach C, Stroyakovskiy D, Lum BL, Elliott R, Weber HA, Ismael G.

Ann Oncol. 2015 Feb;26(2):320-5. doi: 10.1093/annonc/mdu524. Epub 2014 Nov 17.

PMID:
25403587
30.

Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens.

Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B.

Clin Breast Cancer. 2014 Dec;14(6):396-404. doi: 10.1016/j.clbc.2014.06.006. Epub 2014 Aug 15.

PMID:
25239225
31.

Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.

Mackey JR, Ramos-Vazquez M, Lipatov O, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Abi Gerges D, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M.

J Clin Oncol. 2015 Jan 10;33(2):141-8. doi: 10.1200/JCO.2014.57.1513. Epub 2014 Sep 2.

32.

[The use of SPECT-CT in the diagnosis of cancerous lesions of axillary lymph nodes in patients with breast cancer].

Kanaev SV, Novikov SN, Krzhivitskiĭ PI, Krivorot'ko PV, Semiglazov VF, Il'in ND, Briantseva ZhV.

Vopr Onkol. 2014;60(2):51-6. Russian.

PMID:
24919262
33.

[Adjuvant chemotherapy for breast cancer: search for new ways of planning].

Semiglazov VF, Semiglazov VV, Paltuev PM, Dashian GA, Donskikh RV, Komiakhov AV, Krivorot'ko PV, Nikolaev KS, Nikitina IV, Semiglazova TIu.

Vopr Onkol. 2014;60(1):102-8. Russian.

PMID:
24772626
34.

Challenges to effective cancer control in China, India, and Russia.

Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PE, Pramesh CS, Badovinac-Crnjevic T, Sheikine Y, Chen Z, Qiao YL, Shao Z, Wu YL, Fan D, Chow LW, Wang J, Zhang Q, Yu S, Shen G, He J, Purushotham A, Sullivan R, Badwe R, Banavali SD, Nair R, Kumar L, Parikh P, Subramanian S, Chaturvedi P, Iyer S, Shastri SS, Digumarti R, Soto-Perez-de-Celis E, Adilbay D, Semiglazov V, Orlov S, Kaidarova D, Tsimafeyeu I, Tatishchev S, Danishevskiy KD, Hurlbert M, Vail C, St Louis J, Chan A.

Lancet Oncol. 2014 Apr;15(5):489-538. doi: 10.1016/S1470-2045(14)70029-4.

PMID:
24731404
35.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J.

Lancet Oncol. 2014 May;15(6):640-7. doi: 10.1016/S1470-2045(14)70080-4. Epub 2014 Mar 20.

PMID:
24657003
36.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G.

Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14. Review.

PMID:
24529560
37.

Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.

Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, Vazquez F, Gianni L, Baselga J.

Clin Cancer Res. 2014 Jan 15;20(2):511-21. doi: 10.1158/1078-0432.CCR-13-0239.

38.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M.

Ann Oncol. 2014 Mar;25(3):592-8. doi: 10.1093/annonc/mdt543. Epub 2014 Jan 8.

39.

[Protocol of the 500th jubilee meeting of the Society of Oncologists, devoted to the theme of "Hormone-dependent tumors -- pathogenesis and therapy," May 12, 2014].

Beliaev AM, Tsyrlina EV, Bershteĭn LM, Semiglazov VF, Berlev IV, Mikhnin AE.

Vopr Onkol. 2014;60(5):651-4. Russian. No abstract available.

PMID:
25823056
40.

Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.

Rivera E, Chang JC, Semiglazov V, Burdaeva O, Kirby MG, Spector T.

Clin Breast Cancer. 2014 Feb;14(1):26-30. doi: 10.1016/j.clbc.2013.08.018. Epub 2013 Nov 1.

PMID:
24183612
41.

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).

Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, Clark E, Ross G, Swain SM.

Breast Cancer Res Treat. 2013 Nov;142(1):89-99. doi: 10.1007/s10549-013-2710-z. Epub 2013 Oct 16.

42.

Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.

Láng I, Bell R, Feng FY, Lopez RI, Jassem J, Semiglazov V, Al-Sakaff N, Heinzmann D, Chang J.

Clin Oncol (R Coll Radiol). 2014 Feb;26(2):81-9. doi: 10.1016/j.clon.2013.08.011. Epub 2013 Sep 17.

PMID:
24051172
43.

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.

Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group.

Lancet Oncol. 2013 Sep;14(10):962-70. doi: 10.1016/S1470-2045(13)70383-8. Epub 2013 Aug 19.

PMID:
23965225
44.

[Clinical and morphological features and treatment for lobular breast cancer].

Tabagua TT, Semiglazov VV, Bus'ko EA, Semiglazova TIu, Voroshnikov VV.

Vopr Onkol. 2013;59(3):386-9. Russian.

PMID:
23909043
45.

[The effectiveness of ultrasound and sonoelastography in the diagnosis of palpable and non-palpable breast lesions].

Bus'ko EA, Mishchenko AV, Semiglazov VV, Tabagua TT.

Vopr Onkol. 2013;59(3):375-81. Russian.

PMID:
23909041
46.

[Markers of effectiveness of preoperative taxane-based chemotherapy for locally advanced breast cancer].

Semiglazova TIu, Klimenko VV, Filatova LV, Chubenko VA, Krivorot'ko PV, Ivanov VG, Turkevich EA, Ivantsov AO, Novikov SN, Semiglazov VV, Donskikh RV, Moiseenko FV, Bus'ko EA, Briantseva ZhV, Osipov MA, Gershanovish ML, Imianitov EN, Semiglazov VF.

Vopr Onkol. 2013;59(3):363-7. Russian.

PMID:
23909039
47.

[HER2-positive breast cancer: standard and double targeted therapy].

Semiglazov VF, Bozhok AA, Semiglazova TIu, Vasil'ev AG, Manikhas AG, Semiglazov VV, Bessonov AA, Nikolaev KS.

Vopr Onkol. 2013;59(3):341-6. Russian.

PMID:
23909035
48.

[Effectiveness of mammary scintigraphy for determining the results of neoadjuvant polychemotherapy in breast cancer].

Kanaev SV, Krivorot'ko PV, Novikov SN, Semiglazov VF, Semiglzova TIu, Turkevich EA, Zhukova LA, Klimashevskiĭ VF, Ivantsov AO, Donskikh RV, Klimenko VV, Briantseva ZhV.

Vopr Onkol. 2013;59(3):328-33. Russian.

PMID:
23909033
49.

[Possibilities of surgical treatment for disseminated breast cancer].

Bozhok AA, Topuzov ÉÉ, Semiglazov VF, Klimov NA, Kasianova MN, Osianikov AA.

Vopr Onkol. 2013;59(3):320-7. Russian.

PMID:
23909032
50.

[New approaches to the treatment of breast cancer].

Semiglazov VF.

Vopr Onkol. 2013;59(3):288-91. Russian. No abstract available.

PMID:
23909027

Supplemental Content

Loading ...
Support Center